Viral contamination in your biologic product is much more than an annoying setback. It can halt production, delay clinical trials, damage investor confidence, and cost millions. Whether you’re manufacturing monoclonal antibodies, vaccines, or cell and gene therapies, viral safety is a non-negotiable.

The Eurofins BioPharma Product Testing (BPT) network of laboratories provides comprehensive, fully cGMP-compliant viral safety services across all stages of biologic product development and manufacturing. From characterization of cell banks to testing unprocessed bulk and end-of-production materials, our services are designed to reduce risk, ensure compliance, and streamline your timeline to market.

We help developers and manufacturers meet the expectations of global regulatory bodies, and navigate the shift away from animal-based (in vivo) testing. Our technical experts will work with you to determine the best strategy for your product and regulatory pathway, offering in vitro and molecular alternatives when appropriate. 

What sets Eurofins BPT apart is not just the depth of our scientific expertise, but the flexibility and service-first mindset we bring to every client relationship, whether you are an early-stage biotech developer or established CDMO. 

Viral safety testing is a key pillar of the broader Eurofins BPT biosafety offering, providing clarity, transparency, and assurance as your biologic progresses from discovery to commercialization. Our extensive experience with global regulatory submissions will help ensure your product meets the highest standards of safety and integrity, every step of the way.